All Pharma News
AbbVie`s Humira loses some ground in high-stakes battle against biosimilars

AbbVie`s Humira loses some ground in high-stakes battle against biosimilars
FIERCE PHARMA
12 Jul 2024
Share Share
Samsung Bioepis’ PYZCHIVA Approved by FDA as Biosimilar of Stelara

Samsung Bioepis’ PYZCHIVA Approved by FDA as Biosimilar of Stelara
CONTRACT PHARMA
01 Jul 2024
Share Share
FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar

FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar
GLOBENEWSWIRE
01 Jul 2024
Share Share
Samsung Bioepis` Biologic Pyzchiva (ustekinumab-ttwe) Receives Approval in US

Samsung Bioepis` Biologic Pyzchiva (ustekinumab-ttwe) Receives Approval in US
FDA
28 Jun 2024
Share Share
Samsung Bioepis Releases 2024 Sustainability Report on Accessibility and R&D

Samsung Bioepis Releases 2024 Sustainability Report on Accessibility and R&D
GLOBENEWSWIRE
25 Jun 2024
Share Share
Samsung Bioepis Presents EPYSQLI Post-Hoc Analysis At EHA

Samsung Bioepis Presents EPYSQLI Post-Hoc Analysis At EHA
GLOBENEWSWIRE
14 Jun 2024
Share Share
Italy starts probe into Lucentis biosimilar delay allegation

Italy starts probe into Lucentis biosimilar delay allegation
Phil Taylor PHARMAPHORUM
08 Jun 2024
Share Share
Novartis, Roche unit and others face Italy antitrust probe over eye drug

Novartis, Roche unit and others face Italy antitrust probe over eye drug
REUTERS
07 Jun 2024
Share Share
Samsung Bioepis Eculizumab Biosimilar EPYSQLI Post-Hoc Analysis At EHA

Samsung Bioepis Eculizumab Biosimilar EPYSQLI Post-Hoc Analysis At EHA
GLOBENEWSWIRE
30 May 2024
Share Share
Samsung Biosimilar Sb16 Prolia: Switching Period Results At Ects 2024

Samsung Biosimilar Sb16 Prolia: Switching Period Results At Ects 2024
GLOBENEWSWIRE
27 May 2024
Share Share